WuXi Biologics Reports Strong 2022 Interim Results
Revenue Increased by 63.5% Y-o-Y to RMB7,206.4 Million Gross Profit Increased by 48.6% Y-o-Y to RMB3,413.2 Million Net Profit Grew by 39.2% Y-o-Y to RMB2,621.2 Million Adjusted Net Profit Rose by 60.9% to RMB2,914.9 Million Total Backlog Reached US$18,467 Million * * * Non-COVID Re...
WuXi Biologics Again Selected as Constituent of FTSE4Good Index Series
SHANGHAI, Aug. 16, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), announced today that it has once again been selected as a constituent of the FTSE4Good Index Series, and is the only healthcare-se...
WuXi Biologics Plans to Build a Comprehensive CRDMO Center in Singapore
* This investment will establish a cutting-edge, fully integrated CRDMO center inSingapore, including a research and development service center and large-scale drug substance and drug product manufacturing facilities for biologics * The investment strengthens WuXi Biologics' global research, ...
WuXi Vaccines Received First GMP Certificate of QC Potency Lab from Ireland Health Products Regulatory Authority
- The first GMP certificate that WuXi Vaccines has received from the regulatory agency - A critical step for WuXi Vaccines to enable the manufacturing of commercial vaccine products in its Dundalk facility and supplying the global market for a top-10 pharmaceutical company DUNDALK, Ireland, Jul...
WuXi XDC and AbTis Sign Memorandum of Understanding for Development and Manufacturing of Antibody Drug Conjugates
SHANGHAI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- WuXi XDC, a global leading CRDMO (Contract Research, Development and Manufacturing Organization) dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology company dedicated to the development of antibody drug c...
WuXi Biologics Extends Capabilities to Include Development and cGMP Manufacturing for Microbial-Derived Products
* WuXi Biologics expands its extensive integrated CRDMO services by offering development and cGMP manufacturing for microbial-derived products. HANGZHOU, China, July 4, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing ...
WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes
* WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services for clinical trial and commercial supply by increasing pre-filled syringes (PFS) capacity to 17 million units per year. * WuXi Biologics has established a global manufacturing network with 9 drug p...
WuXi Biologics' 2021 ESG Report Reveals Company's Strong Commitment to Overall Sustainability
- WuXi Biologics has aligned its ESG strategy with the United Nations Sustainable Development Goals (SDGs), as well as with its stakeholders' interests in sustainable business performance. - One example of WuXi Biologics' contribution to society is its rapid, robust pandemic response -- enab...
WuXi Biologics Receives Bioprocessing Excellence Award from IMAPAC
SINGAPORE, April 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO) service company, today announced that the company received the award for Bioprocessing Excellence in Viral Clearance and Safety at the A...
WuXi Biologics Achieved Record Growth and Profitability in 2021
Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million Gross Profit Increased by 90.6% Y-o-Y to RMB4,828.9 Million Net Profit Grew by 107.3% Y-o-Y to RMB3,508.6 Million Adjusted Net Profit Rose by 100.3% to RMB3,435.9 Million Total Backlog Grew 20.1% to ...
WuXi Biologics Recognized as 2022 Top-Rated ESG Company by Sustainalytics
SHANGHAI, March 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, has been recognized as the Industry Top-Rated Company in 2022 by Sustainalytics, a global provider of Environmental, Social and Governance (ESG) related research,ratings and data. This ...
WuXi Biologics Wins CMO Leadership Awards in All Six Core Categories for Fifth Consecutive Year
SHANGHAI, March 1, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, today announced that the company has won the 2022 CMO Leadership Awards in all six core categories (i.e., capabilities, compatibility, expertise, reliability, quality and service).2022 m...
WuXi Biologics Statement
SHANGHAI, Feb. 8, 2022 /PRNewswire/ -- We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries inShanghai and Wuxi will be added to the department's "Unverified List" (UVL) on February 8, 2022. We understand that the reason for this a...
WuXi Biologics Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility
* WuXi Biologics completes the first GMP inspection in 2022, demonstrating the company's premier quality system is in full compliance with global regulatory requirements. WUXI, China, Jan. 17, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access ...
WuXi Biologics Launches a New GMP Commercial Drug Product Facility
* Enhances drug product services for projects at various stages, with an emphasis on late and commercial stage production * Increases up to 60 million vials for commercial drug production per year * Consolidates WuXi Biologics' pioneering the application of innovative technologies such as si...
WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility
- Successfully completed nearly 20 regulatory inspections in total, including 13 regulatory inspections since the start of 2021 WUXI, China, Oct. 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced th...
WuXi Biologics Received First Manufacturing License from Japan and Completed 12 Global Regulatory Inspections in 2021 Year to Date
* Successfully completed 12 regulatory inspections so far this year WUXI, China, Sept. 1, 2021 /PRNewswire/ -- WuXi Biologics (WuXi Bio) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has received the Manufacturing License fromJapan'...
WuXi Biologics Reports Strong 2021 Interim Results
* Revenue Increases by 126.7% Y-o-Y to RMB4,406.8 Million * Gross Profit Grows by 191.7% Y-o-Y to RMB2,296.8 Million * Adjusted Net Profit Attributable to Owners of the Company Increases by 163.0% Y-o-Y toRMB1,768.7 Million * Gross and Net Profit Margins Reach 52.1% and 42.7%, Respectively ...
WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate
SUZHOU, China, Aug. 2, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP c...
WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility
* First GMP manufacturing authorization outside of China, validating WuXi Biologics' world-class quality system * Only 12 months from facility qualification to licensure demonstrating global adoption of "WuXi Biologics Speed" LEVERKUSEN, Germany, July 26, 2021 /PRNewswire/ -- WuXi Biologics (...
